Levi & Korsinsky has started an investigation into Biogen Inc. following the failure of its CELIA trial for the BIIB080 Alzheimer's drug, which did not meet its primary endpoint. This led to a sharp decline in Biogen's stock as investors reassessed the company's near-term pipeline value. The investigation focuses on potential violations of federal securities laws related to the company's prior optimistic statements about its drug pipeline. Investors who suffered losses may seek recovery under these laws.
Biogen Inc. announced the appointment of Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and strategic leadership in the biopharmaceutical industry, having held senior roles at Spur The...
The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cogniti...
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
